gip and glp-1 receptor agonist New strategies for the treatment of obesity metabolic dysfunctions Possible mechanisms of the interaction

Hospitals play a crucial role in the distribution of GLP-1 receptor agonists, capturing a significant market share in 2022

Independent of breast cancer mortality, obesity increases the risk of comorbid conditions, including cardiovascular disease (the most common cause of noncancerrelated death in breast cancer patients) and diabetes

104 Furthermore, a mitochondrial injury may play a role in transitioning from diabetes to AD, as exposing diabetic rats brain mitochondria to A increases their vulnerability

Clin Sci

[DOI] [PubMed] [Google Scholar] 58.Kwon G., et al

Moreover, GLP-1R agonism has been associated with the inhibition of NF-B-mediated inflammatory signaling and NLRP3 inflammasome activation, as well as the reduction of angiotensin II-induced fibrosis, possibly through AMPK- and cAMP-independent mechanisms